share_log

Mangoceuticals | 8-K: Current report

Mangoceuticals | 8-K: Current report

Mangoceuticals | 8-K：重大事件
美股SEC公告 ·  06/18 12:54

Moomoo AI 已提取核心信息

On June 17, 2024, Mangoceuticals, Inc. conducted its 2024 Annual Meeting of Stockholders, with a quorum achieved through the presence of 20,115,314 shares, against a total of 24,819,500 shares outstanding as of the record date, May 6, 2024. During the meeting, shareholders voted on six key proposals. The election of directors Jacob D. Cohen, Lorraine D’Alessio, Alex P. Hamilton, and Dr. Kenny Myers was confirmed. Additionally, the issuance of over 19.99% of outstanding common stock upon conversion of Series B Convertible Preferred Stock and certain warrants was approved, in compliance with Nasdaq Listing Rule 5635(d). Similar approval was granted for the issuance of stock pursuant to an Equity Purchase Agreement and for the full issuance of shares related to the 6% Series C Convertible Cumulative Preferred Stock. Turner, Stone & Company, L.L.P. was appointed as the independent auditors for the fiscal year ending December 31, 2024. A proposal to adjourn the meeting for additional proxy solicitation was also approved, but the adjournment was not necessary.
On June 17, 2024, Mangoceuticals, Inc. conducted its 2024 Annual Meeting of Stockholders, with a quorum achieved through the presence of 20,115,314 shares, against a total of 24,819,500 shares outstanding as of the record date, May 6, 2024. During the meeting, shareholders voted on six key proposals. The election of directors Jacob D. Cohen, Lorraine D’Alessio, Alex P. Hamilton, and Dr. Kenny Myers was confirmed. Additionally, the issuance of over 19.99% of outstanding common stock upon conversion of Series B Convertible Preferred Stock and certain warrants was approved, in compliance with Nasdaq Listing Rule 5635(d). Similar approval was granted for the issuance of stock pursuant to an Equity Purchase Agreement and for the full issuance of shares related to the 6% Series C Convertible Cumulative Preferred Stock. Turner, Stone & Company, L.L.P. was appointed as the independent auditors for the fiscal year ending December 31, 2024. A proposal to adjourn the meeting for additional proxy solicitation was also approved, but the adjournment was not necessary.
2024年6月17日，Mangoceuticals公司举行了2024年股东年会，与记录日期2024年5月6日的总共24819500股股票相比，通过20115314股股东出席，达到法定比例。在会上，股东投票表决了六项关键提案，包括确认董事Jacob D. Cohen、Lorraine D’Alessio、Alex P. Hamilton和Dr. Kenny Myers的选举，批准换股B系列可转换优先股和某些认股权所对应的已发行普通股超过19.99%的发行，以符合纳斯达克上市规则5635(d)的要求。同时也批准按照权益购买协议的有关规定发行股票的提案以及六年期C系列可转换优先股的全部股票发行。Turner, Stone & Company, L.L.P.被任命为2024年结束的财政年度的独立审计师。还通过了一项将会议休会，以便进行附加投票征集的提案，但最终没有必要休会。
2024年6月17日，Mangoceuticals公司举行了2024年股东年会，与记录日期2024年5月6日的总共24819500股股票相比，通过20115314股股东出席，达到法定比例。在会上，股东投票表决了六项关键提案，包括确认董事Jacob D. Cohen、Lorraine D’Alessio、Alex P. Hamilton和Dr. Kenny Myers的选举，批准换股B系列可转换优先股和某些认股权所对应的已发行普通股超过19.99%的发行，以符合纳斯达克上市规则5635(d)的要求。同时也批准按照权益购买协议的有关规定发行股票的提案以及六年期C系列可转换优先股的全部股票发行。Turner, Stone & Company, L.L.P.被任命为2024年结束的财政年度的独立审计师。还通过了一项将会议休会，以便进行附加投票征集的提案，但最终没有必要休会。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间